KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Non Operating Income (2016 - 2025)

West Pharmaceutical Services' Non Operating Income history spans 15 years, with the latest figure at $31.7 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 419.67% year-over-year to $31.7 million; the TTM value through Dec 2025 reached -$1.0 million, changed 0.0%, while the annual FY2025 figure was -$1.0 million, 0.0% changed from the prior year.
  • Non Operating Income for Q4 2025 was $31.7 million at West Pharmaceutical Services, up from -$11.9 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $31.7 million in Q4 2025 and bottomed at -$50.0 million in Q3 2022.
  • The 5-year median for Non Operating Income is -$2.2 million (2022), against an average of -$3.4 million.
  • The largest annual shift saw Non Operating Income tumbled 16566.67% in 2022 before it soared 419.67% in 2025.
  • A 5-year view of Non Operating Income shows it stood at -$8.4 million in 2021, then skyrocketed by 353.57% to $21.3 million in 2022, then tumbled by 141.78% to -$8.9 million in 2023, then skyrocketed by 168.54% to $6.1 million in 2024, then skyrocketed by 419.67% to $31.7 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Non Operating Income are $31.7 million (Q4 2025), -$11.9 million (Q3 2025), and -$200000.0 (Q2 2025).